Breaking News

Maravai LifeSciences Expands CDMO Capabilities at TriLink

To increase small molecule manufacturing capacity for additional scale-up of CleanCap messenger RNA capping technology for vaccine and therapeutic programs.

By: Contract Pharma

Contract Pharma Staff

Maravai LifeSciences, a global provider of life science reagents and services, is expanding its contract development and manufacturing organization capabilities at TriLink BioTechnologies for the second time in less than a year. The expansion is expected to be completed in 1Q21 and will increase TriLink’s small molecule manufacturing capacity for additional scale-up of CleanCap, its messenger RNA (mRNA) capping technology, for global mRNA vaccine and therapeutic programs. The company is al...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters